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TRUTH IN ADVERTISING: APPLYING
COMMERCIAL SPEECH REGULATIONS TO
THE SECONDARY DISSEMINATION OF
SCIENTIFIC RESEARCH PUBLICATIONS
CODY CORLISS†
INTRODUCTION
As the biological substance that coats the surface of the
lungs, surfactant is critical to human life. Surfactants play a key
role in lung function by facilitating the transfer of oxygen from
inhaled air into the blood stream. Although the human body
naturally produces surfactants, premature babies often cannot
produce an adequate surfactant level required for proper lung
functioning. As a result, such babies are particularly susceptible
to lung collapse and Respiratory Distress Syndrome, a condition
that can cause respiratory failure and death.
A number of nonbiological surfactant solutions are available
to keep neonatal infants breathing. ONY, a biopharmaceutical
company in New York, produces one such product called
“Infasurf,” which is derived from bovine lung surfactant. ONY’s
chief competitor Chiesi and its American distributor Cornerstone
Therapeutics offer a competing surfactant called “Curosurf,”
which is derived from porcine lung mince.
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The two products compete in the marketplace and champion
the relative superiority of their respective surfactant products.
As part of its research program, Chiesi, the manufacturer of
Curosurf, hired a number of medical doctors to research the
effectiveness of its product. The doctors’ study determined that
neonatal infants using Chiesi’s product are more likely to survive
than neonatal infants given ONY’s Infasurf. After concluding
their research, the doctors published their findings in a medical
journal. Once that scientific article was published, Chiesi and
Cornerstone issued press releases touting the article’s
conclusions and distributed its own promotional materials that
cited and quoted the scientific publication. ONY offered a
vigorous rebuttal: company scientists wrote letters to scientific
journals that rebutted the Chiesi study’s research methodology.
Most interestingly for the purposes of this Article, ONY also filed
suit regarding Chiesi and Cornerstone’s scientific claims, alleging
that use of the scientific article’s conclusions in Chiesi’s
promotional materials violated the Lanham Act.
Is the science in the journal and its resulting promotional
use commercial promotion subject to regulation under the
Lanham Act, the federal statute regulating false advertising and
promotion? The United States Court of Appeals for the Second
Circuit held that it was not1: “[A]s a matter of law, statements of
scientific conclusions about unsettled matters of scientific debate
cannot give rise to liability for damages sounding in
defamation.”2 The court went even further, concluding that “the
secondary distribution of excerpts of such an article cannot give
rise to liability, so long as the excerpts do not mislead a reader
about the conclusions of the article.”3
One year later, the Fifth Circuit took up a different false
advertising case also stemming from the publication of scientific
There, Eastman Chemical Company, the
findings.4
manufacturer of a plastic resin product used in water bottles and
food containers, filed suit against two of its competitors,
Eastman alleged that its
PlastiPure and CertiChem.5
competitors made false and misleading statements in violation of
1
2
3
4
5

ONY, Inc. v. Cornerstone Therapeutics, Inc., 720 F.3d 490, 492 (2d Cir. 2013).
Id.
Id.
Eastman Chem. Co. v. Plastipure, Inc., 775 F.3d 230, 233 (5th Cir. 2014).
Id. at 233–34.
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the Lanham Act when they claimed that Eastman’s products
leached chemicals capable of causing human harm.6 Like in
ONY, a scientific article was the center of the controversy.7 Here,
CertiChem-backed scientists published an article in a peerreviewed scientific journal claiming that Eastman Chemicals
products had the potential to activate estrogen receptors in the
human body and trigger hormone-dependent cancers.8 After
research on the article was completed, but before the article’s
publication, PlastiPure published a three-page sales brochure
that noted the research. The sales brochure contained a chart
that depicted Eastman Chemical’s products as having significant
levels of estrogen-triggering activity (“EA”).9 At trial, the jury
found for Eastman, finding that PlastiPure and CertiChem had
made false advertising statements about Eastman’s product,
thereby violating the Lanham Act.10 The Fifth Circuit agreed
that the Lanham Act applied to the use of the scientific findings
in PlastiPure’s advertising, reasoning that “[a]dvertisements do
not become immune from Lanham Act scrutiny simply because
their claims are open to scientific or public debate.”11
The First Amendment protects academic freedom, scientific
inquiry, and scientific publication, but what protection applies
when scientific findings are distributed as commercial speech
outside their initial academic realm? Commercial speech is
subject to the Lanham Act prohibition against false or misleading
statements of fact used in advertising or promotion. At what
point does protected scientific inquiry transform into commercial
speech that is subject to the stricter Lanham Act scrutiny? These
two recent circuit court decisions have only blurred the
distinction; the two decisions differed on whether commercial
speech standards apply when false or misleading scientific
results are distributed beyond their initial academic spheres.
The result is an uneven judicial landscape on the evaluation of
false advertising claims involving scientific research.
This
Article examines the peculiarities of the Lanham Act and the use
of scientific findings in advertising or promotion. This Article

6

Id. at 234.
ONY, Inc., 720 F.3d at 492.
8
Eastman Chem. Co.,775 F.3d at 233–34.
9
Id.
10
Id. at 234.
11
Id. at 236.
7
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also argues that the Fifth Circuit’s Eastman decision is the better
model than what is used in the Second Circuit.
If the
distribution of noncommercial speech serves any commercial
purpose, the speech becomes commercial and is regulated by the
Lanham Act. Although the Second Circuit noted that “it is the
essence of the scientific method that the conclusions of empirical
research are tentative and subject to revision,”12 the Lanham Act
holds distributers to a higher standard.13 A distributor of
academic statements in advertising or promotion must guarantee
that the statements and findings it distributes are true so as not
to mislead the public. Sophisticated scientists may understand
that academic research articles are subject to later revision, but
the general population is less likely to understand such a
distinction. The ONY holding will immunize advertisers who
rely on science, to the ultimate detriment of consumers who are
likely to believe that scientific findings constitute “facts.”
Part I of this Article examines the Lanham Act generally and
the Act’s regulation of commercial speech. Part II reviews the
interplay between the Lanham Act and the First Amendment
protections afforded to scientific inquiry and scientific
publication. It then examines the secondary dissemination of
scientific findings, arguing that a third party’s dissemination of
the scientific findings or a press release quoting those findings
constitutes commercial speech that should be regulated by the
Lanham Act. This Article explores how the recent ONY decision
has the potential to chill Lanham Act litigation, and it argues
that future decisions following ONY’s logic could foreclose
Lanham Act litigation where the truth of scientific findings may
be at issue. Lastly, this Article contends that future Lanham Act
decisions should instead follow the logic of the Fifth Circuit’s
Eastman decision, which properly keeps the secondary
dissemination of scientific publications under the ambit of the
Lanham Act.

12
13

ONY, Inc., 720 F.3d at 496.
See Eastman Chem. Co., 775 F.3d at 236.
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I. HISTORY OF THE LANHAM ACT & KEY ELEMENTS TO
CONSIDER FOR SCIENTIFIC SPEECH USED IN COMMERCIAL
ADVERTISING
General Background of the Lanham Act Regulating
Commercial Speech

A.

An understanding of the Lanham Act and its effect on
commercial speech can best be understood through an
examination of the history and elements of the Act. As an initial
matter, § 43(a) of the Lanham Act proscribes false statements or
false representations made in commercial advertising or
promotion.14 The Lanham Act provides a private right of action
for unfair competition claims based on false advertising.15 In
recent years, the Lanham Act has become a powerful tool in the
battle for market supremacy. A Lanham Act suit from a
competitor can stall a new or rising entrant in the marketplace
and increase a rival’s cost of doing business.16 Given its power as
a business weapon, an examination of Lanham Act suits suggests
that many are unlikely to have much impact on consumer
welfare.17 Moreover, as one scholar argued, the threat of Lanham
14

Trademark Act of 1946 § 43(a), 15 U.S.C. § 1125(a)(1)(B) (2012).
§ 1125(a)(1).
16
Jean Wegman Burns, Confused Jurisprudence: False Advertising Under the
Lanham Act, 79 B.U. L. REV. 807, 809 (1999).
17
See, e.g., Abdallah v. Pileggi, No. 97-1581, 1998 WL 180491, at *1 (Fed. Cir.
Apr. 17, 1998) (alleging that a company falsely represented that its necktie was
patented); United Indus. Corp. v. Clorox Co., 140 F.3d 1175, 1178 (8th Cir. 1998)
(claiming that an advertisement’s wording and images misrepresented that it killed
roaches within twenty-four hours); Castrol Inc. v. Pennzoil Co., 987 F.2d 939, 941
(3d Cir. 1993) (claiming that a motor oil company deceptively claimed its product
“outperforms any leading motor oil against viscosity breakdown”); Twentieth
Century Fox Film Corp. v. Suarez Corp. Indus., No. 98 Civ. 1711(WK), 1998 WL
126065, at *1 (S.D.N.Y. Mar. 19, 1998) (claiming a necklace was not an authorized
copy of a piece of jewelry in a movie); Avon Prods., Inc. v. S.C. Johnson & Son, Inc.,
984 F. Supp. 768, 796 (S.D.N.Y. 1997) (claiming that a lotion did not actually act as
a bug repellent); Playtex Prods., Inc. v. Gerber Prods. Co., 981 F. Supp. 827, 828
(S.D.N.Y. 1997) (alleging falsity where competitor falsely represented that its cup
was fifty percent easier to drink from than a competitor’s cup); Heublein, Inc. v. E &
J Gallo Winery, Inc., No. 94CIV.9155 (JFK)(AJP), 1995 WL 168846, at *3 (S.D.N.Y.
Apr. 7, 1995) (claiming that an alcoholic drink was mislabeled “Margarita” when it
only contained margarita flavoring and no tequila); Kraft Gen. Foods, Inc. v. Del
Monte Corp., No. 93 CV. 4413, 1993 WL 557864, at *42 (S.D.N.Y. Sept. 22, 1993)
(claiming that “gelatin” was used on a product that was not actually vegetable
based); Complaint at ¶ 3, Sony Comput. Entm’t Am. LLC v. Bridgestone Ams., Inc.,
No. C 12 4753 LB, 2012 WL 4339671 (N.D. Cal. Sept. 11, 2012) (claiming that a tire
15
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Act litigation leads companies to avoid “hard-edged, but truthful,
advertising” in favor of safe, less-informative ads that are less
likely to provide grounds for a Lanham Act suit.18
B.

The History of the Lanham Act and Its 1988 Amendments

In its sixty years of existence, the Lanham Act, the chief U.S.
law regulating commercial speech, has provided a flexible legal
framework to regulate competition in the marketplace.19 An
understanding of the Act and its history is important to
understand the legal interpretations regarding the Lanham Act
and the regulation of commercial speech.20
In 1946, Congress passed the Lanham Act, formally
codifying the federal trademark law,21 to “place all matters
relating to trade-marks in one statute and to eliminate judicial
obscurity, to simplify registration and to make it stronger and
more liberal, to dispense with mere technical prohibitions and
arbitrary provisions, to make procedure simple, and relief
against infringement prompt and effective.”22 Although, in the
words of one court, the Lanham Act brought the “creation of a
‘new statutory tort’ intended to secure a market-place free from
deceitful marketing practices,”23 the Act was rarely invoked for

company’s commercials misled the public when it hired an actor who had previously
appeared in a series of video game commercials).
18
Burns, supra note 16, at 809.
19
See Joseph D. Garon, The Lanham Act: A Living Thing, 7 FORDHAM INTELL.
PROP. MEDIA & ENT. L.J. 55, 56 (1996) (writing that the Lanham Act has proven to
be a flexibility to adapt to vast and unpredictable changes in the business world); id.
at 56 n.6 (“Like our U.S. Constitution which was drafted by the framers to be
applicable and adaptable in any age, so too can the Lanham Act be interpreted to
apply to current legal problems and to deal with changing political, economic and
moral issues.” (quoting Randy Lipsitz, Judging by Appearance: How the Lanham Act
Protects Product Shapes; Issue Continues To Confound Lawyers, N.Y.L.J., Dec. 2,
1996, at S4)).
20
See, e.g., Mark A. Lemley, The Modern Lanham Act and the Death of Common
Sense, 108 Yale L.J. 1687, 1710–15 (1999) (arguing that courts should not construe
the Lanham Act as a broad anticopying statute partly because some commercial
uses of a trademark are important in societal discourse); Rebecca Tushnet,
Trademark Law as Commercial Speech Regulation, 58 S.C. L. REV. 737, 737–39
(2007) (noting the difficulties of establishing clear boundaries between commercial
speech regulated by the Lanham Act and the First Amendment).
21
Lanham Act, Pub. L. No. 79-489, § 46(a), 60 Stat. 427 (1946) (codified as
amended in scattered sections of 15 U.S.C.).
22
S. REP. NO. 79-1333, at 3 (1946), as reprinted in 1946 U.S.C.C.A.N. 1274,
1274.
23
Johnson & Johnson v. Carter-Wallace, Inc., 631 F.2d 186, 189 (2d Cir. 1980).
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the first thirty years following its enactment.24 In the 1970s and
1980s, however, a significant increase in Lanham Act related
litigation greatly expanded the scope of the Act beyond mere
trademark infringement and into the realm of alleged deceitful
statements about products or services.25
Prior to 1988, nearly all Lanham Act cases involved
traditional advertising.26 A revision of the Act by Congress in
1988 set the stage for the further regulation of commercial
speech.27 As part of these revisions, Congress rewrote § 43(a).
The two parts of § 43(a) concern (1) false designations of origins
and (2) false advertising or promotion.28 The pertinent section
reads:
(1) Any person who, on or in connection with any goods or
services, or any container for goods, uses in commerce any word,
term, name, symbol, or device, or any combination thereof, or
any false designation of origin, false or misleading description of
fact, or false or misleading representation of fact, which—
(A) is likely to cause confusion, or to cause mistake, or to deceive
as to the affiliation, connection, or association of such person
with another person, or as to the origin, sponsorship, or
approval of his or her goods, services, or commercial activities
by another person, or
(B) in commercial advertising or promotion, misrepresents the
nature, characteristics, qualities, or geographic origin of his or
her or another person’s goods, services, or commercial activities,
shall be liable in a civil action by any person who believes that
he or she is or is likely to be damaged by such act.29

24
Burns, supra note 16, at 816 (describing the Lanham Act as being “largely
dormant for almost thirty-five years”).
25
See id. at 816–17; Ashley N. Calhoun, Comment, Winking in the Dark: An
Analysis of Corrective-Advertising Damages Under the Lanham Act and the Effect on
the American Economy, 32 STETSON L. REV. 821, 825 (2003).
26
Burns, supra note 16, at 819.
27
See Trademark Law Revision Act of 1988, Pub. L. No. 100-667, § 132, 102
Stat. 3935, 3946 (codified as amended in 15 U.S.C. § 1125(a) (2012)). The
amendments took effect in 1989.
28
15 U.S.C. § 1125(a)(1).
29
Id.
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The legislative history regarding the revisions has increased
confusion, rather than clarified matters.30 The Senate Report
noted that the modifications to § 43(a) were designed “to codify
the interpretation [that § 43(a)] has been given by the courts.”31
Still, as one scholar noted, the 1988 Congressional revisions
overruled some aspects of prior case law.32 For example, where
Congress made the new § 43(a)(1)(B) applicable to the
misrepresentations about a plaintiff’s product, Congress
overruled prior lower court decisions interpreting the original
§ 43(a) to apply only to statements about a defendant’s own
product.33 Legal decisions in the intervening years have largely
established the Lanham Act principles that the 1988
congressional reforms failed to clarify.34
30
See, e.g., Burns, supra note 16, at 820 (writing that the scant legislative
history and the actual text of that history “creates as much confusion as clarity”);
Frank Z. Hellwig, The Trademark Law Revision Act of 1988: The 100th Congress
Leaves Its Mark, 79 TRADEMARK REP. 287, 311 (1989) (noting that “due to a lack of a
unifying legislative history, the drawback is that [§ 43(a)] will continue to be a
source of much controversy and litigation necessary to clarify it”).
31
S. REP. NO. 100-515, at 2 (1988), as reprinted in 1988 U.S.C.C.A.N. 5577,
5603.
32
Burns, supra note 16, at 821 (writing that Congress intentionally overruled
prior case law).
33
See, e.g., U.S. Healthcare, Inc. v. Blue Cross, 898 F.2d 914, 921 (3d Cir. 1990);
Bernard Food Indus., Inc. v. Dietene Co., 415 F.2d 1279, 1283 (7th Cir. 1969); Skil
Corp. v. Rockwell Int’l Corp., 375 F. Supp. 777, 782–83 (N.D. Ill. 1974) (allowing an
action based on false statements in comparative advertising where a defendant
allegedly misrepresented both its product and the plaintiff’s product).
34
For example, although the Lanham Act is often regarded as a consumer
welfare statute and the language of the congressional direction suggested that
consumers were intended to have standing, a recent United States Supreme Court
decision affirmed the widespread federal court decisions that held that Lanham Act
standing is not available to the actual consumers who are injured by false
advertising. Lexmark Int’l, Inc. v. Static Control Components, Inc., 134 S. Ct. 1377,
1388 (2014) (“Read literally, that broad language [of § 43(a)] might suggest that an
action is available to anyone who can satisfy the minimum requirements of Article
III. No party makes that argument, however, and the ‘unlikelihood that Congress
meant to allow all factually injured plaintiffs to recover persuades us that [§ 1125(a)]
should not get such an expansive reading.’ ” (second alteration in original) (quoting
Holmes v. Sec. Inv’r Prot. Corp., 503 U.S. 258, 266 (1992))); see also Conte Bros.
Auto., Inc. v. Quaker State-Slick 50, Inc., 165 F.3d 221, 229 (3d Cir. 1998)
(“Conferring standing to the full extent implied by the text of § 43(a) would give
standing to parties, such as consumers, having no competitive or commercial
interests affected by the conduct at issue.”), abrogated by Lexmark Int’l, Inc., 134 S.
Ct. at 1391–93. Federal courts have unanimously rejected the right of consumers to
bring a suit under the Lanham Act. Lexmark Int’l, Inc. 134 S. Ct. at 1390 (“A
consumer who is hoodwinked into purchasing a disappointing product may well have
an injury-in-fact cognizable under Article III, but he cannot invoke the protection of
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The Lanham Act’s Key Elements

To prevail on a false advertising claim, the traditional
analysis is that a plaintiff must prove five elements: (1) the
existence of a defendant’s false statement of fact about its own or
another product in a commercial advertisement; (2) that the
statement actually deceived or had the tendency to deceive a
substantial segment of the audience; (3) materiality—that is,
likelihood that a purchasing decision was influenced—of the
deception; (4) that the statement entered interstate commerce
due to the defendant; and (5) injury or likelihood of injury to the
plaintiff, whether by loss of sales to defendant or loss of goodwill
associated with plaintiff’s products, as a result of the defendant’s
false statement.35 Interstate commerce is an element of the
Lanham Act that is nearly always met.36 In addition, the injury

the Lanham Act—a conclusion reached by every Circuit to consider the question.”).
Instead, standing confers to competitors or others active in the marketplace that
might be harmed by false representations in commercial speech. Id. (“[A] plaintiff
must allege an injury to a commercial interest in reputation or sales.”); Harold H.
Huggins Realty, Inc. v. FNC, Inc., 634 F.3d 787, 798 (5th Cir. 2011) (“Deterioration
of competitive position is precisely the kind of injury the Lanham Act was intended
to redress.”). Industry competitors or another company active in the marketplace
must bring suit against the company allegedly engaging in false or misleading
advertising or promotion. Id. at 797.
35
Wells Fargo & Co. v. ABD Ins. & Fin. Servs., Inc., 758 F.3d 1069, 1071 (9th
Cir. 2014); Newcal Indus., Inc. v. Ikon Office Sol., 513 F.3d 1038, 1052 (9th Cir.
2008); Scotts Co. v. United Indus. Corp., 315 F.3d 264, 272 (4th Cir. 2002); WarnerLambert Co. v. Breathasure, Inc., 204 F.3d 87, 91–92 (3d Cir. 2000); United Indus.
Corp. v. Clorox Co., 140 F.3d 1175, 1180 (8th Cir. 1998); Skil Corp., 375 F. Supp at
782–83.
36
Given the nature of advertising and promotion, the interstate commerce
requirement is rarely invoked in a Lanham Act defense and is even less likely to
succeed. It has long been acknowledged that the Lanham Act “confers broad
jurisdictional powers upon the courts of the United States.” Steele v. Bulova Watch
Co., 344 U.S. 280, 283 (1952); see also U.S. Healthcare, Inc., 898 F.2d at 922 (“The
commerce requirement has been broadly interpreted.”). There are, however, certain
instances where the interstate commerce requirement is not met, such as where the
advertising or promotion is solely of a local variety. See, e.g., Goldberg v. Bell Atl.,
No. 99 Civ. 2889 (DC), 2000 WL 1459834, at *4 (S.D.N.Y. Sept. 29, 2000) (“[A]ll of
the factual allegations suggest the statements were made exclusively in Rockland
County—that they were ‘purely local.’ The complaint alleges that the wrongful acts
occurred within the Southern District of New York, that the yellow pages in question
were compiled and published for Rockland County, that the directories were
distributed ‘county wide’ in Rockland County, and that Donnelley was the ‘exclusive’
agent for soliciting advertisements in Rockland County. There is nothing to suggest,
and plaintiffs do not allege, that the purported wrongful statements were made
anywhere other than in Rockland County (and within New York State).” (citation
omitted)); Licata & Co., Inc. v. Goldberg, 812 F. Supp. 403, 409 (S.D.N.Y. 1993) (“The
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requirement, which requires the plaintiff to show economic or
reputational harm directly flowing from the false advertising or
promotion event, is likely to be met if the false advertising comes
in the context of marketplace competition.37 As a result, this
Article will not address these two elements in the discussion
below.
The elements themselves appear to have little more than a
historical accident, originating in a 1974 district court decision.38
That decision, which did not conduct a formal analysis of the
named false advertising elements, cited as its only authority a
1956 law review article that had formulated the elements based
solely on pre-Lanham Act case law.39
1.

False or Misleading Statement of Fact

As an initial matter, it is unquestionable that a literally false
statement made in commercial speech is grounds for a Lanham
Act claim. If a statement is actually false, relief can be granted
on the court’s own findings without reference to the reaction of
the buyer or consumer of the product.40 Establishing the truth of
a scientific question can be a difficult analysis. Section 43(a)

Lanham Act’s reach, while long, does not extend to the full outer limits of the
commerce power.”).
37
The plaintiff must show economic or reputational injury flowing directly from
the deception wrought by the defendant’s advertising, “and that occurs when
deception of consumers causes them to withhold trade from the plaintiff.” Lexmark
Int’l, Inc., 134 S. Ct. at 1391. Moreover, courts have been cognizant that reputational
harm resulting from the sale of falsely labeled products is difficult to prove, and an
erosion of consumer confidence in a product can take time to fully develop. See
Camel Hair & Cashmere Inst. of Am., Inc. v. Associated Dry Goods Corp., 799 F.2d
6, 13 (1st Cir. 1986). Still, there are some limits to the ability to prove injury, such as
where a court rejected a Lanham Act claim where the plaintiff presented “nothing
beyond mere conjecture with regard to the anticipated harm to [its] reputation. And,
significantly, [Plaintiff] has experienced an increase in sales since the industry
became aware of Defendants’ mistake.” Riverdale Mills Corp. v. Cavatorta N. Am.,
Inc., 146 F. Supp. 3d 356, 362 (D. Mass. 2015) (rejecting a Lanham Act claim
regarding the composition of lobster fishing nets where alleged false statements
occurred for an isolated period of time, Defendant ceased selling of the alleged
mislabeled product, Defendant took steps to inform customers of labeling product,
Defendant took steps to inform customers of labeling issue, and where Plaintiff’s
sale actually increased in the period in question).
38
See Skil Corp., 375 F. Supp. at 782–83.
39
See id. at 783 (citing Gilbert H. Weil, Protectability of Trademark Values
Against False Competitive Advertising, 44 CALIF. L. REV. 527, 537 (1956)).
40
Am. Brands, Inc. v. R. J. Reynolds Tobacco Co., 413 F. Supp. 1352, 1357
(S.D.N.Y. 1976).
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cases often require judges and juries to make factual
determinations on technical, scientific, or medical issues in which
they have little background or expertise.41
Misleading statements are equally actionable. The vast
majority of false advertising cases have recognized that even
statements that are “literally” true can similarly mislead
consumers and are therefore actionable under § 43(a).42 As one
court explained, if false advertising law merely prohibited literal
falsehoods, “clever use of innuendo, indirect intimations, and
ambiguous suggestions could shield the advertisement from
scrutiny precisely when protection against such sophisticated
deception is most needed.”43
As the Lanham Act makes actionable any false or misleading
statement of fact, a statement of opinion is not actionable.44
Congress added the words “of fact” to the original version of the
section in the 1988 amendments to avoid a First Amendment
constitutional challenge.45 Though the United States Court of
Appeals for the Second Circuit recognized that “the line between

41
See, e.g., C.B. Fleet Co., Inc. v. SmithKline Beecham Consumer Healthcare,
L.P., 131 F.3d 430, 437 (4th Cir. 1997) (noting that the district court conducted a
three-day trial focused largely on expert testimony related to scientific tests);
Castrol Inc. v. Pennzoil Co., 799 F. Supp. 424, 427 (D.N.J. 1992) (deciding claims
regarding motor oil’s effect on viscosity breakdown and engine wear), aff’d, 987 F.2d
939 (3d Cir. 1993); McNeil-P.P.C., Inc. v. Bristol-Myers Squibb Co., Inc., 755 F.
Supp. 1206, 1217–18 (S.D.N.Y 1990) (basing decision on medical studies), aff’d, 938
F.2d 1544 (2d Cir. 1991); Procter & Gamble Co. v. Chesebrough-Pond’s Inc., 588 F.
Supp. 1082, 1093–94 (S.D.N.Y. 1984) (describing seven days of testimony from more
than a dozen expert witnesses, including statisticians, dermatologists, chemists, and
physicists, noting that “much of their testimony was incomprehensible”), aff’d, 747
F.2d 114 (2d Cir. 1984).
42
Rebecca Tushnet, Running the Gamut from A to B: Federal Trademark and
False Advertising Law, 159 U. PA. L. REV. 1305, 1320 (2011).
43
Am. Home Prods. Corp. v. Johnson & Johnson, 577 F.2d 160, 165 (2d Cir.
1978).
44
See, e.g., Milkovich v. Lorain Journal Co., 497 U.S. 1, 20 (1990) (“[A]
statement of opinion relating to matters of public concern which does not contain a
provably false factual connotation will receive full constitutional protection.”);
Eastman Chem. Co. v. PlastiPure, Inc., 775 F.3d 230, 234 (5th Cir. 2014) (“Essential
to any claim under [§] 43(a) of the Lanham Act is a determination of whether the
challenged statement is one of fact—actionable under [§] 43(a)—or one of general
opinion—not actionable under [§] 43(a).” (quoting Pizza Hut, Inc. v. Papa John’s
Int’l, Inc., 227 F.3d 489, 495–96 (5th Cir. 2000))); Groden v. Random House, Inc., 61
F.3d 1045, 1051 (2d Cir. 1995) (“[S]tatements of opinion are generally not the basis
for Lanham Act liability.”).
45
134 CONG. REC. H10420 (daily ed. Oct. 19, 1988) (statement of Rep.
Kastenmeier).
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fact and opinion is not always a clear one,”46 a fact is one that can
be proven through some verification or establishment of
certainty.47
“A plaintiff can succeed on a false advertising claim by
proving either that the defendant’s advertisement is literally
false or implicitly false—that is, the advertisement is true or
Where the advertisement is
ambiguous yet misleading.”48
literally false, a violation may be established without evidence of
consumer deception.49 Where the advertisement is implicitly
false, however, “an additional burden is placed upon the plaintiff
to show that the advertisement . . . conveys a misleading
message to the viewing public.”50
Different burdens of proof exist depending upon whether the
suit seeks injunctive relief or monetary damages under the
Lanham Act.51 Showing that the defendant’s activities are likely
to cause confusion or to deceive customers is sufficient to warrant
injunctive relief, but a plaintiff seeking monetary damages must
show actual harm to its business.52
Has the Tendency To Deceive—a Likelihood of Confusion
Standard by Another Name

2.

To be actionable under the Lanham Act, a plaintiff must do
more than merely demonstrate that a statement of fact used in
advertising or promotion is false or misleading. In addition, the
Lanham Act requires plaintiffs to demonstrate that the alleged
misrepresentation deceived a substantial portion of the
46

ONY, Inc. v. Cornerstone Therapeutics, Inc., 720 F.3d 490, 496 (2d Cir. 2013).
Eastman Chem. Co., 775 F.3d at 235 (“[T]he challenged statement must make
a ‘specific and measurable claim, capable of being proved false or of being reasonably
interpreted as a statement of objective fact.’ ” (internal quotation marks omitted)
(quoting Pizza Hut, Inc., 227 F.3d at 496)); Presidio Enters, Inc. v. Warner Bros.
Distrib. Corp., 784 F.2d 674, 679 (5th Cir. 1986) (defining a statement of fact as “one
that (1) admits of being adjudged true or false in a way that (2) admits of empirical
verification”).
48
Cashmere & Camel Hair Mfrs. Inst. v. Saks Fifth Ave., 284 F.3d 302, 311 (2d
Cir. 2002).
49
Balance Dynamics Corp. v. Schmitt Indus., Inc., 204 F.3d 683, 693 (6th Cir.
2000) (noting that “when a statement is literally false, a plaintiff need not
demonstrate actual customer deception in order to obtain relief”).
50
Clorox Co. P.R. v. Proctor & Gamble Commercial Co., 228 F.3d 24, 33 (1st Cir.
2000).
51
Cashmere & Camel Hair Mfrs. Inst., 284 F.3d at 311.
52
Quabaug Rubber Co. v. Fabiano Shoe Co., 567 F.2d 154, 160–61 (1st Cir.
1977).
47
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consuming public.53
Plaintiffs whose claims allege that a
statement is literally false do not need to prove consumer
deception.54 Literally false advertisements are presumptively
deceptive,55 and courts will presume that consumer confusion
existed.56
When evaluating whether an advertising claim is literally
false, the claim must always be analyzed in its full context.57
Consequently, a claim can be literally false “by necessary

53
See Wells Fargo & Co. v. ABD Ins. & Fin. Servs., Inc., 758 F.3d 1069, 1071
(9th Cir. 2014); Clorox Co. P.R., 228 F.3d at 33 n.6; Johnson & Johnson-Merck
Consumer Pharm. Co. v. Rhone-Poulenc Rorer Pharm., Inc., 19 F.3d 125, 129 (3d
Cir. 1994); Pfizer, Inc. v. Miles, Inc., 868 F. Supp. 437, 442 (D. Conn. 1994) (“The
[Lanham Act] embraces false impressions, innuendo and ambiguous suggestions.”).
54
See B. Sanfield, Inc. v. Finlay Fine Jewelry Corp., 168 F.3d 967, 971 (7th Cir.
1999) (“Where the statement in question is actually false, then the plaintiff need not
show that the statement either actually deceived consumers or was likely to do so.”);
Castrol Inc. v. Pennzoil Co., 987 F.2d 939, 943 (3d Cir. 1993) (“[A] plaintiff must
prove either literal falsity or consumer confusion, but not both.” (emphases
omitted)); Johnson & Johnson v. GAC Int’l, Inc., 862 F.2d 975, 977 (2d Cir. 1988)
(“When a . . . representation is literally or explicitly false, the court may grant relief
without reference to the advertisement’s impact on the buying public.” (quoting
Coca-Cola Co. v. Tropicana Prods., Inc., 690 F.2d 312, 317 (2d Cir. 1982))).
55
See Balance Dynamics Corp. v. Schmitt Indus., Inc., 204 F.3d 683, 693 (6th
Cir. 2000) (“Because proof of ‘actual confusion’ can be difficult to obtain, most of the
circuits have rules that when a statement is literally false, a plaintiff need not
demonstrate actual customer deception in order to obtain relief under the Lanham
Act.” (citation omitted)).
56
See, e.g., Pizza Hut, Inc. v. Papa John’s Int’l, Inc., 227 F.3d 489, 497 (5th Cir.
2000) (“[W]hen the statements of fact at issue are shown to be literally false, the
plaintiff need not introduce evidence on the issue of the impact the statements had
on consumers.”); Porous Media Corp. v. Pall Corp., 110 F.3d 1329, 1334–35, 1337
(8th Cir. 1997) (determining that proof of consumer confusion was unnecessary
where a jury determines that a defendant advertised in bad faith); William H.
Morris Co. v. Group W, Inc., 66 F.3d 255, 258 (9th Cir. 1995) (“If [defendant]
intentionally misled consumers, we presume consumers were in fact deceived . . . .”);
Johnson & Johnson-Merck Consumer Pharm. Co., 19 F.3d at 131 (presuming
consumer injury where plaintiff proves intent to deceive and egregious conduct);
Coca-Cola Co., 690 F.2d at 317 (“When a merchandising statement or representation
is literally or explicitly false, the court may grant relief without reference to the
advertisement’s impact on the buying public.”); Am. Brands, Inc. v. R. J. Reynolds
Tobacco Co., 413 F. Supp. 1352, 1356 (S.D.N.Y. 1976) (“[A] court can grant relief on
its own findings without recourse to a survey of consumer reaction.”).
57
Castrol Inc., 987 F.2d at 946; Am. Home Prod. Corp. v. FTC, 695 F.2d 681,
687 (3d Cir. 1982); Cuisinarts, Inc. v. Robot-Coupe Int’l Corp., No. 81 Civ 731-CSH,
1982 WL 121559, at *2 (S.D.N.Y. June 9, 1982) (“[I]n determining facial falsity the
court must view the face of the statement in its entirety, rather than examining the
eyes, nose, and mouth separately and in isolation from each other.”).
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implication.”58 Still, to prove that an advertising claim based on
product testing is literally false, “a plaintiff must do more than
show that the tests supporting the challenged claim are
unpersuasive.”59 Additionally, the plaintiff must demonstrate
that such tests are not sufficiently reliable to permit one to
conclude with reasonable certainty that the tests established the
claim made.60 To meet such a standard, a plaintiff may attack
the validity of the defendant’s tests directly or use other scientific
testing to show that the defendant’s tests are contradicted or
unsupported.61 Moreover, if the plaintiff can show that the tests,
even if reliable, do not establish the proposition asserted by the
defendant, the plaintiff has obviously met its burden of
demonstrating literal falsity.62
In the absence of the allegation of a literal falsity, the
plaintiff must show that the advertisement, though explicitly
true, nonetheless conveys a misleading message to the viewing
public.63 To satisfy its burden, the plaintiff must show how
consumers have actually reacted to the challenged advertisement
rather than merely demonstrating how they could have reacted.64
58
Castrol Inc., 987 F.2d at 946; Tambrands, Inc. v. Warner-Lambert Co., 673 F.
Supp. 1190, 1193–94 (S.D.N.Y. 1987).
59
McNeil-P.C.C., Inc. v. Bristol-Myers Squibb Co., 938 F.2d 1544, 1549 (2d Cir.
1991); see also Procter & Gamble Co. v. Chesebrough-Pond’s, Inc., 747 F.2d 114, 119
(2d Cir. 1984).
60
McNeil-P.C.C., Inc., 938 F.2d at 1549; Procter & Gamble Co., 747 F.2d at 119.
61
Castrol, Inc., 977 F.2d at 62–63 (distinguishing product superiority claim not
based on testing, which must be proven false by affirmative evidence, from product
superiority claim explicitly or implicitly based on tests or studies, which may be
proven false by showing that the tests did not establish the proposition for which
they were cited).
62
Id. at 63.
63
See United Indus. Corp. v. Clorox Co., 140 F.3d 1175, 1183 (8th Cir. 1998)
(stating that when there is no finding of a willful violation or an intent to deceive,
evidence of consumer impact is essential—usually through consumer or market
research—unless the commercial claim is literally false); Sandoz Pharm. Corp. v.
Richardson-Vicks, Inc., 902 F.2d 222, 228 (3d Cir. 1990) (“[A] Lanham Act plaintiff
must prove deceptiveness in court.”).
64
See Cottrell, Ltd. v. Biotrol Int’l, Inc., 191 F.3d 1248, 1256 (10th Cir. 1999)
(holding that if the plaintiff can establish by consumer surveys or other means that
the defendant’s advertising is likely to confuse or actually confuses consumers, any
false implication is as damaging for a Lanham Act claim as an express false claim);
Johnson & Johnson * Merck Consumer Pharm. Co. v. Smithkline Beecham Corp.,
960 F.2d 294, 298 (2d Cir. 1992) (requiring plaintiff to demonstrate that a
“statistically significant part of the commercial audience holds the false belief
allegedly communicated by the challenged advertisement”); Sandoz Pharm. Corp.,
902 F.2d at 228–29 (“[Where an advertising statement is not literally false, the]
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Consumer deception is often demonstrated through surveys
that establish that consumers were misled by the alleged
misrepresentations.65 For example, in a suit involving the
naming, labeling, and advertising of a competitor’s juice product,
the plaintiff claimed that the defendant’s product misled
consumers regarding the quantity of pomegranate in its juices.66
To support its claim, the plaintiff offered a field survey that
showed a thirty-five percent differential between the test and
control groups who mistakenly believed that the defendant’s
product mainly contained pomegranate and blueberry juice,
rather than a fruit juice blend where pomegranate and blueberry
are the third and fourth most used juices.67 Though the
defendant challenged the plaintiff’s survey methodology and
applicability, the district court determined that consumer
deception was a disputed question of fact, and, consequently, the
court denied summary judgment.68 In cases involving alleged
consumer confusion, the court has generally set a fairly low
threshold bar for consumer deception demonstrated through
surveys in order for a claim to proceed.69

plaintiff bears the burden of proving actual deception by a preponderance of the
evidence. Hence, it cannot obtain relief by arguing how consumers could react; it
must show how consumers actually do react.”).
65
See Johnson & Johnson v. Carter-Wallace, Inc., 631 F.2d 186, 191 (2d Cir.
1980) (claiming consumers were misled by defendant’s ad that claimed its product
contained baby oil through introducing surveys that indicated that some people,
after viewing defendant’s ads, thought they would not have to use baby oil if they
used defendant’s product); see also Johnson & Johnson * Merck, 960 F.2d at 298; UHaul Int’l, Inc. v. Jartran, Inc., 522 F. Supp. 1238, 1249–50 (D. Ariz. 1981).
66
POM Wonderful LLC v. Coca Cola Co., 727 F. Supp. 2d 849, 856 (C.D. Cal.
2010), aff'd in part, vacated in part, remanded sub nom. Pom Wonderful LLC v.
Coca-Cola Co., 679 F.3d 1170 (9th Cir. 2012), rev’d, 134 S. Ct. 2228 (2014).
67
Id. at 857–58.
68
Id. at 875–76 (holding that, though the district court recognized questions
regarding the reliability of the survey, “whether the Field Survey actually meets the
Daubert standards is best considered at trial”).
69
Novartis Consumer Health, Inc. v. Johnson & Johnson-Merck Consumer
Pharm. Co., 290 F.3d 578, 594 (3d Cir. 2002) (finding that 15.5% would be sufficient
to support a finding of substantial consumer confusion); Coca-Cola Co. v. Tropicana
Prods., Inc., 690 F.2d 312, 317 (2d Cir. 1982) (holding that a consumer survey that
demonstrated 7.5% consumer deception constituted “a significant number of
consumers . . . likely to be misled”).
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Materiality

The materiality prong requires the plaintiff to demonstrate
that the other party’s falsities or misrepresentations were “likely
to influence the purchasing decision” of consumers,70 though
some commentators argue that, in practice, the materiality
analysis merges with the second prong regarding an
The materiality
advertisement’s tendency to deceive.71
requirement recognizes that not all alleged deceptions affect
consumer purchasing decisions,72 thereby allowing courts to
implement a common-sense approach to the materiality

70
Aristotle Int’l, Inc. v. NGP Software, Inc., 714 F. Supp. 2d 1, 9 (D.D.C. 2010)
(quoting Cashmere & Camel Hair Mfrs. Inst. v. Saks Fifth Ave., 284 F.3d 302, 311
(1st Cir. 2002)); see also 3M Innovative Prop. Co. v. Dupont Dow Elastomers LLC,
361 F. Supp. 2d 958, 971 (D. Minn. 2005) (“Materiality . . . considers whether the
false or misleading statement is likely to make a difference to purchasers.” (internal
quotation mark omitted) (quoting Cashmere & Camel Hair Mfrs. Inst., 284 F.3d at
312 n.10)); Am. Brands, Inc. v. R. J. Reynolds Tobacco Co., 413 F. Supp. 1352, 1357
(S.D.N.Y. 1976) (“[W]e are asked to determine whether a statement acknowledged to
be literally true and grammatically correct nevertheless has a tendency to mislead,
confuse or deceive. As to such a proposition the public’s reaction to (the)
advertisement will be the starting point in any discussion of the likelihood of
deception.” (internal quotation mark omitted) (quoting 1 RUDOLF CALLMANN, THE
LAW OF UNFAIR COMPETITION, TRADEMARKS & MONOPOLIES § 19.2(a)(1) (3d ed.
1967))).
71
For example, some commentators contend that the second and third elements
merge in a practical Lanham Act legal analysis so that the “materiality” element
only requires deception or the capacity to deceive. Given that the language of § 43(a)
does not speak of “materiality” per se, the elements often combine to be a false or
material statement that is material in that it deceives or is likely to deceive.
Moreover, although courts require a showing of “likely effect on consumer decisions,”
this is in connection with the fifth element, proving the fact or threat of injury to a
claimant. See Courtland L. Reichman & M. Melissa Cannady, False Advertising
Under the Lanham Act, 21 FRANCHISE L.J. 187, 187–88 (2002) (noting the merging
of elements in many Lanham Act analyses).
72
William H. Morris Co. v. Grp. W, Inc., 66 F.3d 255, 258 (9th Cir. 1995)
(holding that a letter from the distributor of a dietary supplement did not affect
purchasing decisions because only three percent of pharmacists interviewed
interpreted the letter as referring to plaintiff’s product); U.S. Healthcare, Inc. v.
Blue Cross, 898 F.2d 914, 922 (3d Cir. 1990) (stating that misrepresentations in an
advertisement must “influence the purchasing decision” of the buying public to
satisfy the materiality requirement).
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analysis.73 For example, the materiality requirement allows the
court to accept certain advertising campaigns as puffery if the
claims are sufficiently vague to prevent consumer confusion.74
As one scholar has argued, on a practical basis, the
materiality test also serves an effective gatekeeping function for
the courts.75 Materiality is a mixed question of law and fact,76
and as a result, a court can dismiss a case on the pleadings or on
summary judgment if the plaintiff fails to make a sufficient
showing.77 Still, materiality is not a particularly significant
burden for plaintiffs; evidence of materiality can come through
consumer surveys that are already employed in standard false
advertising litigation.78 Alternatively, where a survey question is
so distant from the questions a consumer is likely to ask in a
73
Nat’l Basketball Ass’n v. Sports Team Analysis & Tracking Sys., Inc., 939 F.
Supp. 1071, 1110 (S.D.N.Y. 1996), aff'd in part, vacated in part sub nom. Nat’l
Basketball Ass’n v. Motorola, Inc., 105 F.3d 841 (2d Cir. 1997) (“The insignificance of
the statement ‘from the arena’ is illustrated further by omitting it entirely from the
clause in which it is found. If the clause simply stated, ‘Nationwide game updates,’ I
find it difficult to envision (and NBA has not shown otherwise) that consumers
suddenly would reassess their decisions to purchase SportsTrax.”).
74
Tushnet, supra note 42, at 1344–45 (“Materiality, among other concepts,
allows courts to bless certain ad claims on their face as nonactionable
puffery. . . . [I]t is the law that consumers are irrebuttably presumed not to rely on
sufficiently vague or exaggerated claims.”).
75
Burns, supra note 16, at 882.
76
See, e.g., Nat’l Basketball Ass’n, 105 F.3d at 855 (holding that even if claim is
literally false, plaintiff must still show materiality); Am. Tel. & Tel. Co. v. Winback
& Conserve Program, Inc., 42 F.3d 1421, 1428 n.9 (3d Cir. 1994) (plaintiff alleging
false advertising must prove “that the deception is material in that it is likely to
influence purchasing decisions”); ALPO Petfoods, Inc. v. Ralston Purina Co., 913
F.2d 958, 964 (D.C. Cir. 1990) (false or misleading ads must be “material in their
effects on buying decisions”); Taquino v. Teledyne Monarch Rubber, 893 F.2d 1488,
1500 (5th Cir. 1990) (deception must be “material, in that it is likely to influence the
purchasing decision”); Tire Kingdom, Inc. v. Morgan Tire & Auto, Inc., 915 F. Supp.
360, 366 (S.D. Fla. 1996) (granting summary judgment on claim because, even if
false, the representation was not material); Compaq Comput. Corp. v. Procom Tech.,
Inc., 908 F. Supp. 1409, 1426–27 (S.D. Tex. 1995) (dismissing claim based on
technically false picture that was found to have little chance of misleading
customers).
77
See Burns, supra note 16, at 882 (arguing that the materiality element allows
the court to function as a gatekeeper to spurious false advertising claims).
78
See, e.g., Johnson & Johnson * Merck Consumer Pharm. Co. v. Smithkline
Beecham Corp., 960 F.2d 294, 298 (2d Cir. 1992) (stating consumer surveys may be
used to establish consumer confusion); Vidal Sassoon, Inc. v. Bristol–Myers Co., 661
F.2d 272, 275–76 (2d Cir. 1981) (stating consumer preference studies were used to
prove consumer confusion). But see Tushnet, supra note 42, at 1347 (“Materiality
can also be used more indirectly to evaluate the relevance of survey evidence that
allegedly shows a likelihood of consumer confusion.”).
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marketplace context, courts may determine that the value of
questions renders the survey unreliable.79 Given a general trust
of science, the materiality prong is particularly likely to be met
where there are claims of scientific validity to support the
promotion. Consumers are likely to perceive as true such claims
that appear to be based upon scientific evidence.80
These elements—(1) a false or misleading statement of fact,
(2) with a tendency to deceive, and that (3) materially affects a
consumer purchasing decision—constitute the key elements
required for a traditional analysis of a false advertising claim.
As the next Part demonstrates, determining what constitutes
commercial speech falling under the purview of the Lanham Act
can be a challenging endeavor. Such analysis is particularly
complicated when the speech in question involves scientific
inquiry that is protected by the First Amendment.
II. ONY’S POTENTIAL CHILLING EFFECT ON LANHAM ACT
LITIGATION
Taken to its logical conclusion, the United States Court of
Appeals for the Second Circuit’s ONY decision has the potential
to foreclose adjudication of false advertising disputes in
industries where marketing relies heavily upon scientific
validation. As discussed below, the publication of scientific
research is protected First Amendment speech, and courts have
often been cautious to allow the regulation of commercial speech
to intrude upon the protection of First Amendment speech rights.
The ONY decision, which would allow commercial entities to
adopt and distribute the language of academic publications
without regulation under the Lanham Act, is a step too far.
Under ONY, a commercial entity could immune itself from a
Lanham Act claim by creating marketing based upon scientific
articles in academic publications without regard to the veracity
of the scientific findings upon which the marketing is based.
79
See Procter & Gamble Co. v. Kimberly–Clark Corp., 569 F. Supp. 2d 796,
804–05 (E.D. Wis. 2008) (finding that a survey asking which of the parties’ diapers
had a more “natural fit” posed an epistemological question that survey evidence
could not satisfactorily answer).
80
See POM Wonderful LLC v. Coca Cola Co., 727 F. Supp. 2d 849, 857–58 (C.D.
Cal. 2010) (consumers are likely to perceive certain types of claims, such as health
and nutrition claims, as being based upon scientific evidence), aff’d in part, vacated
in part, remanded sub nom. POM Wonderful LLC v. Coca-Cola Co., 679 F.3d 1170
(9th Cir. 2012), rev’d, 134 S. Ct. 2228 (2014).
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Scientific Journals, the Lanham Act, and the First
Amendment

The Lanham Act only prohibits false “commercial
advertising or promotion,” namely commercial speech81 The core
notion of commercial speech, as defined by the United States
Supreme Court, is “speech which does no more than propose a
Under its broadest definition,
commercial transaction.”82
commercial speech is an “expression related solely to the
economic interests of the speaker and its audience.”83
The definition of advertising and promotion under the
Lanham Act extends beyond traditional advertising campaigns,
however.84 For example, § 43(a) has been found applicable to the
fundraising letters of a nonprofit pregnancy counseling group,85
to the distribution of marketing information to retailers at a
trade show,86 and has even been found to extend to an
individual’s “badmouthing” of her former employer in telephone
calls made to colleagues and friends.87 In effect, the standard has
become that while the false representations need not be made in
a classic advertising campaign, the representation must be in the
context of commercial speech, the representation must be made
for the purposes of consumers to purchase goods or services, and
81

15 U.S.C. § 1125(a)(1)(B) (2012).
See City of Cincinnati v. Discovery Network, Inc., 507 U.S. 410, 422 (1993)
(quoting Bolger v. Youngs Drug Prods. Corp., 463 U.S. 60, 66 (1983)); see also Bolger,
463 U.S. at 68 (holding that informational pamphlets addressing “important public
issues[,] such as venereal disease and family planning,” constituted commercial
speech where communications were conceded to be advertisements in that they
referred to specific products sold by the defendant, and that the defendant had an
economic motivation for the speech).
83
City of Cincinnati, 507 U.S. at 422.
84
Gordon & Breach Sci. Publishers S.A. v. Am. Inst. of Physics, 859 F. Supp.
1521, 1534–35 (S.D.N.Y. 1994).
85
Birthright v. Birthright, Inc., 827 F. Supp. 1114, 1138 (D.N.J. 1993).
86
Am. Needle & Novelty, Inc. v. Drew Pearson Mktg., Inc., 820 F. Supp. 1072,
1078 (N.D. Ill. 1993) (recognizing that “[t]he level of circulation required to
constitute advertising and promotion will undeniably vary from industry to industry
and from case to case”).
87
Nat’l Artists Mgmt. Co., Inc. v. Weaving, 769 F. Supp. 1224, 1235 (S.D.N.Y.
1991) (“It is true that defendants’ conduct—speaking by telephone with a number of
friends, acquaintances, and colleagues about the reasons for terminating their
relationships with [the company]—is not ‘commercial advertising and promotion’ in
the traditional sense of large-scale, nationwide commercial advertising campaigns.
In the context of the theatre-booking industry, however, ‘services’ are ‘promoted’ by
word-of-mouth and information is spread through a network of telephone contacts
with producers, promoters, and presenters.”).
82
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the representation must be disseminated sufficiently to the
relevant purchasing public to constitute “advertising” or
“promotion” within that industry.88
B.

Scientific Articles as Protected Speech

Given that the Lanham Act has the potential to chill First
Amendment speech rights, courts have been somewhat reluctant
to extend the reach of the Lanham Act into areas that may
intrude upon the First Amendment.89 Academic research is one
such area. For example, the Supreme Court has determined that
academic freedom, including academic scientific research,
constitutes a “special concern of the First Amendment.”90
The First Amendment protects “scientific speech.”91
Consequently, a debate that takes place in academic journals is
part of the marketplace of ideas protected by the First
As a result, the publication of an article
Amendment.92
addressing scientific findings in a peer-reviewed journal does not
constitute commercial speech, even if there is the potential for
erroneous content.93
In addition to “pure” science articles, there is the publication
of an article that appears to serve dual masters. From one
perspective, this article can be speech that is noncommercial in
nature and addresses a significant public issue, thereby
88

Gordon & Breach Sci. Publishers S.A., 859 F. Supp. at 1535–36.
Boule v. Hutton, 328 F.3d 84, 91 (2d Cir. 2003) (noting the general approach
of being “careful not to permit overextension of the Lanham Act to intrude on First
Amendment values” (quoting Groden v. Random House, Inc., 61 F.3d 1045, 1052 (2d
Cir. 1995))).
90
Keyishian v. Bd. of Regents, 385 U.S. 589, 603 (1967).
91
Miller v. California, 413 U.S. 15, 34 (1973) (“The First Amendment protects
works which, taken as a whole, have serious literary, artistic, political, or scientific
value, regardless of whether the government or a majority of the people approve of
the ideas these works represent.”); Bd. of Trs. of Leland Stanford Junior Univ. v.
Sullivan, 773 F. Supp. 472, 474 (D.D.C. 1991) (“It is equally settled, however, though
less commonly the subject of litigation, that the First Amendment protects scientific
expression and debate just as it protects political and artistic expression.”).
92
Gordon & Breach Sci. Publishers S.A., 859 F. Supp. at 1541 (citing Keyishian,
385 U.S. at 603).
93
See, e.g., Bracco Diagnostics, Inc. v. Amersham Health, Inc., 627 F. Supp. 2d
384, 456 (D.N.J. 2009) (“[T]here is an abundance of case law to support the
proposition that a scientific article is protected noncommercial speech despite the
potential for erroneous content.”); Sullivan, 773 F. Supp. at 474 (“It is equally
settled, however, though less commonly the subject of litigation, that the First
Amendment protects scientific expression and debate just as it protects political and
artistic expression.”).
89
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constituting protected speech under the First Amendment.94
From another perspective, however, such speech appears to
propose a commercial transaction that would be regulated under
the Lanham Act.95
Although the context was informational pamphlets rather
than academic articles, the Supreme Court examined the nature
of intertwined “commercial” and “noncommercial” speech in
Bolger v. Youngs Drug Products Corp.96 In Bolger, the Court
examined the application of a federal statute that prohibited the
mailing of unsolicited advertisements for contraceptives.97
Youngs, a pharmaceuticals wholesaler, sought to undertake a
campaign of unsolicited mass mailings promoting its products,
including contraceptives, to the general public.98 The majority of
Youngs’s mailings consisted primarily of price and quantity
information, and these mailings fell within the core notion of
Other mailings, however, were less
commercial speech.99
explicitly commercial: these mailings consisted of informational
pamphlets with titles such as “Condoms and Human Sexuality”
and “Plain Talk about Venereal Disease.”100 The pamphlets
included references, of varying degrees of prominence, to Youngs
and its Trojan-brand condoms.101
The Supreme Court
acknowledged that a mere economic motivation for the mailing is
insufficient to render the materials commercial speech.102 The
same is true for a simple reference to a commercial product.103
Though the Court recognized the commercial speech issue to be a
close question, it concluded that “[t]he combination of all these

94
Gordon & Breach Sci. Publishers S.A., 859 F. Supp. at 1539 (presenting,
“from one perspective . . . the aspect of protected, noncommercial speech addressing
a significant public issue, but which, from another perspective, appears primarily to
be speech ‘proposing a commercial transaction.’ ”).
95
Id.
96
463 U.S. 60 (1983).
97
Id. at 61–62.
98
Id. at 62.
99
Id. at 66.
100
Id. at 62 n.4.
101
Id. (noting that for pamphlets regarding venereal disease, “[t]he only
identification of Youngs or its products [was] at the bottom of the last page of the
pamphlet, which state[d] that the pamphlet ha[d] been contributed as a public
service by Youngs, the distributor of Trojan-brand prophylactics”).
102
Id. at 66–67.
103
Id.
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characteristics . . . provides strong support for the . . . conclusion
that the informational pamphlets are properly characterized as
commercial speech.”104
Courts applying this mixed commercial-noncommercial
analysis to academic works have generally found their
publication to be noncommercial and, therefore, outside the reach
of the Lanham Act.105 For example, the United States District
Court for the Southern District of New York found that an article
containing comparative surveys of scientific journals that rated
its own publications as superior did not constitute commercial
speech.106 The nonprofit publisher’s potential financial benefit
was not outcome determinative.107 Similarly, the author of the
book The Cure for All Cancers suggested that readers refrain
from ingesting a manufacturer’s vitamins because the vitamins
contained an ingredient that was allegedly carcinogenic.108 The
court held that allegedly false statements about the vitamin did
not constitute commercial speech because “the commercial
elements of the speech [were] intertwined with the central
message” that was noncommercial in nature.109 Additionally, a
nonprofit medical association’s publication of an article that
contained allegedly false statements about the defendant’s
electrodiagnostic medical devices did not constitute commercial
speech because the authors of the article did not advocate for a
commercial transaction.110 Even if some of the language in the
article was commercial in nature, the article’s public significance
and status as an academic piece published by a nonprofit
organization meant it was noncommercial speech.111

104

Id. at 67.
Gordon & Breach Sci. Publishers S.A., v. Am. Inst. Of Physics, 859 F. Supp.
1521, 1541, 1545 (S.D.N.Y. 1994).
106
Id. at 1523, 1545.
107
Id. at 1541 (“The fact that AIP and APS stood to benefit from publishing
Barschall’s results—even that they intended to benefit—is insufficient by itself to
turn the articles into commercial speech.”).
108
Oxycal Labs., Inc. v. Jeffers, 909 F. Supp. 719, 720 (S.D. Cal. 1995).
109
Id. at 725.
110
Neurotron, Inc. v. Am. Ass’n of Electrodiagnostic Med., 189 F. Supp. 2d 271,
277 (D. Md. 2001) (“The Technology Review is published by AAEM, a non-profit
organization, whose purpose is not only to lobby and advocate for its members, but
also to provide educational services such as informing members of current trends in
the industry through publications such as Muscle & Nerve, or by conducting
educational seminars. None of these activities are commercial in nature.”).
111
Id.
105
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Still, the publication of an article may constitute commercial
speech if the statements in the article were made for an explicitly
commercial purpose. For example, the United States Court of
Appeals for the Sixth Circuit determined that the publication of
an article in a trade-based journal fell under the ambit of the
Lanham Act because the article contained demonstrably false
information about a product that was likely to influence a
purchasing decision.112 Here, a trade journal asked the president
of a manufacturer of beryllium-copper plunger tips to write an
article about the manufacture of plunger tips.113 The article
submitted by the company president contained a number of selfserving statements about his company’s products.114 The journal,
after removing some of the most self-serving comments,
published the article.115 After the article’s publication, the
defendant-manufacturer obtained reprints, made numerous
copies, and used the article as a promotional brochure at trade
shows.116 A competitor filed suit, arguing that the article itself
amounted to false advertising or promotion and violated the
Lanham Act.117 The Sixth Circuit agreed, holding that the article
in the trade publication constituted commercial speech, and that
any false statements would be actionable under the Lanham
Act.118
C.

Scientific Statements in Academic Publications: Statements
of Fact or Opinion?

In ONY, the Second Circuit held that a pharmaceutical
manufacturer’s dissemination of an academic article and the
company’s press release quoting those scientific findings did not
constitute commercial speech.119 Because the Lanham Act only
prohibits false or misleading statements of fact, statements of
112
Semco, Inc. v. Amcast, Inc., 52 F.3d 108, 113–14 (6th Cir. 1995) (holding that
an article was commercial speech under the Lanham Act where the publication
author “presented an article peppered with advertising for Amcast—and that
advertising, which the trade publication did not solicit, allegedly contained material
misrepresentations of Amcast products”).
113
Id. at 110.
114
Id.
115
Id.
116
Id. at 111.
117
Id. at 110.
118
Id. at 114.
119
ONY, Inc. v. Cornerstone Therapeutics, Inc., 720 F.3d 490, 492 (2d Cir.
2013).
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opinion are outside the bounds of traditional Lanham Act
analysis.120 The Second Circuit’s ONY analysis determined that
scientific discourse constitutes opinion, thereby finding that
scientific discourse falls outside the scope of Lanham Act
regulation.121 Still, the Second Circuit recognized that scientific
academic discourse poses a peculiar problem in the fact-opinion
paradigm.122 Facts are statements that can be verified,123 and the
very nature of scientific publication is to establish facts that hold
up to rigorous research and testing.124
Moreover, most
conclusions in scientific journal articles are “capable of
verification or refutation by means of objective proof.”125 While
these scientific conclusions are subject to proof, the Second
Circuit has argued that the essence of the scientific method is
marked by tentative conclusions.126 A key point in the Second
Circuit’s ONY analysis is that these scientific statements are
made for the scientific community and not for the general
public.127 As the Second Circuit explained, “These conclusions
are then available to other scientists who may respond by
attempting to replicate the described experiments, conducting
their own experiments, or analyzing or refuting the soundness of
the experimental design or the validity of the inferences drawn
from the results.”128 Therefore, although the matters presented

120

15 U.S.C. § 1125(a)(1) (2012).
ONY, Inc., 720 F.3d at 497–98.
122
Id. at 496–97.
123
Presidio Enters., Inc. v. Warner Bros. Distrib. Corp., 784 F.2d 674, 679 (5th
Cir. 1986) (“A statement of fact is one that (1) admits of being adjudged true or false
in a way that (2) admits of empirical verification.”).
124
ONY, Inc., 720 F.3d at 496 (“Indeed, it is the very premise of the scientific
enterprise that it engages with empirically verifiable facts about the universe.”).
125
Phantom Touring, Inc. v. Affiliated Publ’ns, 953 F.2d 724, 728 n.7 (1st Cir.
1992).
126
ONY, Inc., 720 F.3d at 496 (“[I]t is the essence of the scientific method that
the conclusions of empirical research are tentative and subject to revision, because
they represent inferences about the nature of reality based on the results of
experimentation and observation.”).
127
Id. at 496–97 (“Importantly, those conclusions are presented in publications
directed to the relevant scientific community, ideally in peer-reviewed academic
journals that warrant that research approved for publication demonstrates at least
some degree of basic scientific competence.”).
128
Id. at 497.
121
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within scientific journal articles might be verifiable, the Second
Circuit determined that information offered in scientific journals
is more akin to opinion.129
In contrast, the Fifth Circuit’s Eastman decision offers a
more balanced approach. As that court made clear, “it is of no
moment that the commercial speech in this case concerned a
topic of scientific debate. Advertisements do not become immune
from Lanham Act scrutiny simply because their claims are open
to scientific or public debate.”130 As the Fifth Circuit suggested,
the distribution of scientific literature or a scientific article for
promotional purposes transforms that speech into commercial
speech that may be regulated by the Lanham Act.131
D. Distribution Transforms Noncommercial Speech into
Commercial Speech
In addition to holding that the publication of statements and
research results do not constitute facts under the Lanham Act,
the Second Circuit in ONY determined that the subsequent
distribution of the article was similarly not commercial speech.132
Although the court used explicit language holding that
distribution of the article did not trigger the Lanham Act, the
Second Circuit’s analysis only considered whether publication of
the article was commercial speech itself, finding that it was
not.133 Given that it was not commercial speech, the Second
Circuit concluded that further dissemination of the article was
similarly inactionable.134

129
Id. (“[W]hile statements about contested and contestable scientific
hypotheses constitute assertions about the world that are in principle matters of
verifiable ‘fact,’ for purposes of the First Amendment and the laws relating to fair
competition and defamation, they are more closely akin to matters of opinion, and
are so understood by the relevant scientific communities.”).
130
Eastman Chem. Co. v. PlastiPure, Inc., 775 F.3d 230, 236 (5th Cir. 2014).
131
Id. at 237.
132
ONY, Inc., 720 F.3d at 492 (“We conclude that, as a matter of law,
statements of scientific conclusions about unsettled matters of scientific debate
cannot give rise to liability for damages sounding in defamation. We further
conclude that the secondary distribution of excerpts of such an article cannot give
rise to liability, so long as the excerpts do not mislead a reader about the conclusions
of the article.”).
133
Id. at 497–98 (addressing the dissemination of the article only in the context
of tortious interference claims and dismissing those claims on the basis that
dissemination of the article was not misleading).
134
Id.
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As a practical matter, ONY seems to run counter to the
stringent requirements in place with respect to the Food and
Drug Administration’s (“FDA”) analysis of pharmaceuticals. The
FDA regulates all forms of prescription drug advertising,
including direct-to-consumer advertising, thereby ensuring that
the advertising claims are supported by credible evidence.135 The
FDA evaluates scientific studies and determines whether they
support the health-related claims the manufacturer wishes to
make for the drug. If the FDA finds the study insufficient, the
claim may not be legally made. A manufacturer may not claim
that a substance treats, cures, or diagnoses a disease without
FDA approval. Moreover, a pharmaceutical manufacturer cannot
circumvent such a requirement by merely asserting that “study X
supports” such a panacea.
The Second Circuit’s ONY analysis has a number of
problems. As an initial matter, the dissemination of an article is
a separate step from the writing and publication of one.
Although the writing of scientific articles falls within the First
Amendment
protections
for academic
freedom,136
the
dissemination of that article by a company is a separate step
deserving additional scrutiny.137 As the Fifth Circuit noted, “The
First Amendment ensures a robust discourse in the pages of
academic journals, but it does not immunize false or misleading
commercial claims.”138 Consequently, the distribution of an
article may have commercial implications beyond the academic
speech.139
Second, the general distribution of a scientific article will
extend the reach of the scientific findings beyond the small,
specialized audience of the scientific community. In its ONY
decision, the Second Circuit noted that conclusions in scientific
journals are directed to the relevant scientific community.140

135

21 C.F.R. § 202.1(j)(1)(i)-(ii) (2017).
See, e.g., Keyishian v. Bd. of Regents, 385 U.S. 589, 603 (1967).
137
See Zauderer v. Office of Disciplinary Counsel, 471 U.S. 626, 638 (1985) (“The
States and the Federal Government are free to prevent the dissemination of
commercial speech that is false, deceptive, or misleading . . . .”).
138
Eastman Chem. Co. v. PlastiPure, Inc., 775 F.3d 230, 237 (5th Cir. 2014).
139
Id.
140
ONY, Inc. v. Cornerstone Therapeutics, Inc., 720 F.3d 490, 496–97 (2d Cir.
2013) (“[I]t is the essence of the scientific method that the conclusions of empirical
research are tentative and subject to revision, because they represent inferences
about the nature of reality based on the results of experimentation and observation.
136
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While such an observation is certainly true, a company’s
distribution of a scientific article moves the scientific findings
from the scientific community and into the realm of the general
public. Moreover, because the public is the ultimate consumer of
a medical product, any distribution of the article beyond a small
subset of academic researchers is likely to reach members of the
general public.141 The general public has much less knowledge
about the science in question and likely lacks an in-depth
understanding of the research methodology used to achieve the
scientific results.142 Even a targeted distribution to doctors,
health care providers, or those within the greater scientific
community is likely to reach individuals with less ability to
analyze the scientific methodology and weigh the studies’
conclusions compared to those who read the article in a
specialized scientific journal.143
Notably, the Second Circuit in ONY determined that a
subsequent press release touting the scientific findings did not
transform scientific speech into commercial speech. As the ONY
decision notes, “After the article’s publication, Chiesi and
Cornerstone issued a press release touting its conclusions and
distributed promotional materials that cited the article’s
findings.”144 Such a holding is contrary to earlier case law.

Importantly, those conclusions are presented in publications directed to the relevant
scientific community . . . .”).
141
See Kos Pharm., Inc. v. Andrx Corp., 369 F.3d 700, 715 n.12 (3d Cir. 2004)
(noting the increasing prevalence of prescription medication advertisements that are
aimed directly at influencing patient choices).
142
For a general analysis of how the public analyzes scientific evidence, see
Jennifer L. Mnookin, Idealizing Science and Demonizing Experts: An Intellectual
History of Expert Evidence, 52 VILL. L. REV. 763, 767 (2007) (“Our desire to idealize
science runs, I fear, rather deep; we do not actually want science to be muddy,
complex, pragmatic, methodologically imperfect and messy. When the science offered
in court is all of these things, as it so often is, we therefore tend to blame the science
itself, rather than our own unrealistic desires.”). Similarly, writing about jurors’
analyses of scientific evidence, Valerie Hans notes that “jurors themselves have
identified the task of interpreting scientific and technical evidence . . . as
particularly challenging.” Valerie P. Hans, Judges, Juries, and Scientific Evidence,
16 J.L. & POL’Y 19, 23 (2007).
143
See, e.g., Genzyme Corp. v. Shire Human Genetic Therapies, Inc., 906 F.
Supp. 2d 9, 17 (D. Mass. 2012) (“[A] pharmaceutical manufacturer’s selective
promotion of favorable scientific information could be potentially misleading even to
sophisticated and experienced doctors.”).
144
ONY, Inc., 720 F.3d at 495.
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Instead, most courts agree that a company’s accompanying
press release or explanatory letter touting its scientific findings
constitutes commercial speech and therefore triggers regulation
under the Lanham Act.145
For example, the secondary
dissemination to potential customers of a survey article from the
New England Journal of Medicine comparing two x-ray contrast
media in a head-to-head competition constituted commercial
speech that could be regulated under the Lanham Act.146 As the
Massachusetts District Court made clear, “The press release was
not a scientific publication.”147 Given that a press release has a
target audience beyond a specific scientific community, a
manufacturer’s press release moves the speech out of First
Amendment-protected scientific expression and into the realm of
regulated commercial speech.148
145
See United States v. Harkonen, No. C 08-00164 MHP, 2009 WL 1578712, at
*6 (N.D. Cal. June 4, 2009) (“That the speech is a press release and not a peerreviewed publication, that it refers to a specific commercial product on the
market . . . and that it was unquestionably disseminated for commercial benefit (e.g.,
the first line notes [defendant]’s Nasdaq stock symbol), are allegations that take the
speech at issue outside the realm of pure science speech and move it towards the
realm of commercial speech.”).
146
See Bracco Diagnostics, Inc. v. Amersham Health, Inc., 627 F. Supp. 2d 384,
458–59 (D.N.J. 2009); see also Genzyme Corp., 906 F. Supp. 2d at 16 (“[W]hile the
original presentation of the comparative data at the EWGGD convocation was
protected scientific expression, its secondary dissemination in a press release by
Shire HGT was not.”).
147
Genzyme Corp., 906 F. Supp. 2d at 16–17 (noting, also, that “the press
release selectively disseminated information favorable to Shire HGT’s VPRIV and
unflattering to Cerezyme to an audience that included both physicians who prescribe
Gaucher disease treatments and patients (e.g., those served by the National
Gaucher Foundation) who might request a specific treatment”).
148
Id. at 17. (noting that “the press release selectively disseminated information
favorable to Shire HGT’s VPRIV and unflattering to Cerezyme to an audience that
included both physicians who prescribe Gaucher disease treatments and patients
(e.g., those served by the National Gaucher Foundation) who might request a
specific treatment”); see also Washington Legal Found. v. Friedman, 13 F. Supp. 2d
51, 62–65 (D.D.C. 1998) (finding that a secondary dissemination of that research
constitutes commercial speech if it is given a pecuniary gloss), vacated in part on
other grounds sub nom. Washington Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir.
2000). In Washington Legal Foundation, the court considered whether, under the
commercial speech doctrine, the FDA could regulate the dissemination of medical
textbook and journal reprints and continuing medical education (“CME”) seminars
that promote off-label uses for prescription drugs. The court concluded that selective
and/or targeted secondary dissemination of scientific research “is properly classified
as commercial speech.” Id. at 65. “It is beyond dispute that when considered outside
of the context of manufacturer promotion of their drug products, CME seminars,
peer-reviewed medical journal articles[,] and commercially-available [sic] medical
textbooks merit the highest degree of constitutional protection.” Id. at 62. However,
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Similarly, academic speech is not immune from the Lanham
Act when it is further disseminated. Nonprofit organizations are
free to publish on any topic, even those that lead to their
financial benefit, without fear of Lanham Act liability, but the
same does not apply to subsequent or prior promotional uses of
that speech.149 As the Southern District of New York explained:
The situation is similar to that of a restaurant or movie review
or a Consumer Reports product report. While the restaurant
review or product report itself constitutes exactly the type of
“consumer or editorial comment” that “raise[s] free speech
concerns” and which Congress explicitly intended to exclude
from [§] 43(a)’s scope, a restaurant clearly engages in
commercial speech when it posts the New York Times review in
its window, and General Motors engages in commercial speech
when it announces in a television commercial that its car was
ranked first by Consumer Reports. The Consumer Reports
article, of course, does not somehow become commercial speech;
rather, G.M.’s use of the article is commercial speech.
Consequently, G.M. may be sued under the Lanham Act, and
Consumer Reports’[s] testing methodology may become subject
to judicial scrutiny to determine whether G.M. “use[d] in
commerce” a “false or misleading representation of fact.”150

The fact that the First Amendment protected the initial creation
is immaterial when that creator uses the speech for a secondary
use.151
The distribution of a scientific article is further complicated
because the Lanham Act is a strict liability statute, and whether
the defendant intended to deceive consumers is immaterial to
any legal analysis.152 If a statement or scientific finding is false
or misleading when used in commercial speech, the defendant is
liable. A plaintiff does not need to show intent to deceive,
knowledge of falsity, or even negligence on the part of the

“[t]he peculiarities of the prescription drug industry make dissemination of scientific
research results an especially important and prevalent marketing tool.” Id. at 63.
149
Gordon & Breach Sci. Publishers S.A. v. Am. Inst. of Physics, 859 F. Supp.
1521, 1544–45 (S.D.N.Y. 1994) (holding that, while the publication of a comparative
survey of academic publishers was protected speech under the First Amendment,
the dissemination of the results to librarians were subject to the Lanham Act).
150
Id. at 1544 (first and fourth alterations in original) (citation omitted).
151
Id. at 1544–45.
152
See, e.g., POM Wonderful LLC v. Purely Juice, Inc., 362 F. App’x 577, 579
(9th Cir. 2009) (“It is settled that intent is not an element of a Lanham Act false
advertising claim.”).
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defendant in order to succeed with a claim.153 For a defendant,
honest intentions or good intent is no defense.154 Where a hard,
verifiable statement is made that is capable of scientific
verification, courts and agencies will assume that the recipient of
the communication will treat the statement as including an
implicit representation by the advertiser that such verification
has been made.155 Misstatements in advertising cannot be
protected by ambiguities and relied upon as defenses.156
As an advertising vehicle, “scientific establishment claims”
that rely on a scientific study in order to establish the superiority
of one product over another are particularly effective.157 As a
result, case law has consistently applied a stricter standard of
review for marketing activities that purport to be based on
scientific testing158 or that compare one company’s product with
that of a competitor.159
153
See, e.g., Johnson & Johnson v. Carter-Wallace, Inc., 631 F.2d 186, 189 (2d
Cir. 1980) (stating that the false advertising tort “differs from the common law
action for trade disparagement in two important respects: (1) it does not require
proof of intent to deceive, and (2) it entitles a broad range of commercial parties to
relief”); Am. Broad. Co. v. Maljack Prods., Inc., 34 F. Supp. 2d 665, 677 (N.D. Ill.
1998) (“[In a false advertising suit about footage of Princess Diana’s funeral, the]
BBC’s good faith but mistaken belief in its copyright is not a defense to an action
under § 43(a). ‘The well-settled rule is that there is no requirement under the
Lanham Act that a false representation be made willfully or with the intent to
deceive.’ ” (quoting Zenith Elecs. Corp. v. Exzec, Inc., No. 93 C 5041, 1997 WL
798907, at *12 (N.D. Ill. Dec. 24, 1997))).
154
See, e.g., Am. Broad. Co., 34 F. Supp. 2d at 677 (“[The] BBC’s good faith but
mistaken belief in its copyright is not a defense to an action under § 43(a).”).
155
See, e.g., Am. Home Prods. Corp. v. Johnson & Johnson, 577 F.2d 160, 169
(2d Cir. 1978) (analyzing competing Lanham Act claims by the producers of over-thecounter pain medications where advertising claims were based on clinical trials).
156
Id. at 166.
157
Charles J. Walsh & Marc S. Klein, From Dog Food to Prescription Drug
Advertising: Litigating False Scientific Establishment Claims Under the Lanham
Act, 22 SETON HALL L. REV. 389, 392 (1992) (citing research that notes the
effectiveness of comparative advertising that includes a source of higher credibility).
158
See, e.g., Rhone-Poulenc Roror Pharm., Inc. v. Marion Merrell Dow, Inc., 93
F.3d 511, 514–15 (8th Cir. 1996) (holding that “where defendant has hyped the claim
of superiority by attributing it to the results of scientific testing, plaintiff must prove
only ‘that tests [relied upon] were not sufficiently reliable to permit one to conclude
with reasonable certainty that they established the proposition for which they were
cited.’ ” (alteration in original) (quoting Castrol, Inc. v. Quaker State Corp., 977 F.2d
57, 62–63 (2d Cir. 1992))).
159
See, e.g., Castrol Inc. v. Pennzoil Co., 987 F.2d 939, 944 (3d Cir. 1993)
(enjoining claims that Pennzoil motor oil outperformed Castrol motor oil with
respect to viscosity breakdown); McNeil-P.C.C., Inc. v. Bristol-Myers Squibb Co., 938
F.2d 1544, 1549 (2d Cir. 1991) (enjoining claims that Excedrin was scientifically
superior to Tylenol at relieving pain); Church & Dwight Co. v. Clorox Co., 840 F.
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CONCLUSION
The United States Supreme Court has noted that
“advertising which ‘links a product to a current public debate’ is
not thereby entitled to the constitutional protection afforded
noncommercial speech.”160 ONY has the potential to blur this
rule and further complicate the already-complex jurisprudence
surrounding the regulation of commercial speech. The ONY
decision sets a precedent that could foreclose adjudication of false
advertising disputes in industries where marketing relies heavily
on claims based upon scientific validation. Under ONY, an
advertiser could immune itself to a Lanham Act claim by simply
relying on peer-reviewed scientific articles in academic
publications. These scientific articles would be outside the scope
of the Lanham Act, even if the author of the scientific journal
article received financial support from the future advertiser.161
The Eastman decision returns the boundaries between
commercial and noncommercial speech to their appropriate
spheres. Under Eastman, advertisers are responsible for the
truth of the material they distribute—including the use of peerreviewed academic articles—in advertising or promotion,
regardless of its original source. As the United States Court of
Appeals for the Fifth Circuit noted, the application of the
Lanham Act will not stifle academic freedom or intrude on the
First Amendment.162 The Lanham Act only applies to statements
made “in connection with any advertising, promotion, offering for
sale, or sale of goods or services.”163 Under Eastman, scientists
and academics will continue to be able to research and publish.

Supp. 2d 717, 722–23 (S.D.N.Y. 2012) (enjoining commercial claims as literally false
because tests supporting the claims regarding each party’s cat litter were
unreliable).
160
Bolger v. Youngs Drug Prods. Corp., 463 U.S. 60, 68 (1983) (quoting Cent.
Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n, 447 U.S. 557, 563 n.5 (1980)); see
also Eastman Chem. Co. v. PlastiPure, Inc., 775 F.3d 230, 236 (5th Cir. 2014)
(“Advertisements do not become immune from Lanham Act scrutiny simply because
their claims are open to scientific or public debate.”).
161
See ONY, Inc. v. Cornerstone Therapeutics, Inc., 720 F.3d 490, 493–94, 497
(2d Cir. 2013) (noting that advertiser Chiesi hired several medical doctors to present
findings regarding infant mortality rates, and that these findings ultimately led to
publication in the peer-reviewed journal).
162
Eastman Chem. Co., 775 F.3d. at 237 (“Application of the Lanham Act to
Appellants’ promotional statements will not stifle academic freedom or intrude on
First Amendment values.”).
163
Id.
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It is only those who distribute or use those research findings in
subsequent advertising or promotion who could find themselves
subject to a Lanham Act claim.164
Although the ONY decision may seem on its face to only
impact the use of science in advertising, the decision has the
potential to greatly affect the public. First, as noted earlier, the
decision has the potential to foreclose adjudication of false
advertising disputes in industries where marketing relies heavily
upon scientific validation.
Most significantly, a company’s
distribution of a scientific article moves the scientific findings
from the scientific community and academics and into the realm
of the general public, which is more likely to trust scientific
claims and much less likely to understand or investigate the
research methodology behind those scientific claims. For that
reason, the Fifth Circuit’s Eastman decision reflects the proper
scope of the Lanham Act’s application for the use of scientific
research findings.

164
Id. (“Appellants may continue to pursue their research and publish their
results; they simply may not push their product by making the claims the jury found
to be false and misleading.”).

